Halozyme closes $150 million royalty-backed debt transaction
 

Halozyme Therapeutics, Inc. today announced that it has closed the previously announced $150 million royalty-backed debt transaction with investment funds managed by Pharmakon Advisors and Athyrium Capital Management. The debt is secured by future royalties of ENHANZE products, received only from Halozyme's collaborations with Roche and Baxalta.

More...